Children hospitalized for COVID-19 during the first winter of the pandemic in Buenos Aires, Argentina

Silvina Raiden¹, MD, PhD

Hector Cairoli¹, MD

Javier Potasnik¹, MD

Sandra Di Lalla¹, MD

María José Chiolo¹, MD

Fernando Torres², MD, PhD

Paula Dominguez², MD

Fernando Ferrero¹, MD, PhD

Corresponding author: Fernando Ferrero (fferrero@intramed.net)

Hospital General de Niños Pedro de Elizalde

Av. Montes de Oca 40, C1270AAN Buenos Aires, Argentina

Tel/Fax: +54 11 43070140

Email: fferrero@intramed.net

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

¹ Departamento de Medicina, Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina

² Docencia e Investigación, Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina

ABSTRACT

Background: Although there are reports on COVID-19 in pediatrics, it is possible that the

characteristics of each population, their health systems and how they faced the pandemic

made the disease show distinctive features in different countries.

Objective: We aimed to describe the characteristics of patients hospitalized for COVID-19 in

a tertiary pediatric hospital in the City of Buenos Aires, Argentina.

Methods: Descriptive study, including all patients hospitalized for COVID-19 in a tertiary

pediatric hospital, from 04/26/2020 to 10/31/2020. Demographic, clinical and

epidemiological characteristics of the patients are described.

Results: In the studied period 578 patients were hospitalized for COVID-19. The median age

was 4.2 years and 83% had a history of close contact with a confirmed COVID-19 case.

Regarding severity, 30.8% were asymptomatic, 60.4% mild, 7.4% moderate, and 1.4%

severe. Among those with symptoms, the most frequent was fever, followed by sore throat

and cough.

Conclusion: We reported 578 cases of children and adolescents hospitalized for COVID-19,

most of them showed a mild or asymptomatic condition.

Keywords: Coronavirus infection; COVID-19; pneumonia

INTRODUCTION

Despite the COVID-19 pandemic has caused hundreds of thousands of deaths worldwide, the information available to date shows that the disease is less severe in the pediatric population [1,2].

Also, there are reports that seem to show that the development of the pandemic may be influenced by the characteristics of each country, its health systems and how they faced the pandemic [3,4].

In addition to the characteristics of its own population and health system, Argentina faced the pandemic in a particular way, including the longest lockdown [5] and mandatory hospitalization of affected infants, regardless of its severity [6]. These characteristics could give a distinctive feature to children hospitalized for this disease.

We aimed to describe the characteristics of patients hospitalized for COVID-19 in a pediatric tertiary hospital in the City of Buenos Aires.

METHODS

Retrospective study, including all patients hospitalized for COVID-19 at the tertiary pediatric hospital in Buenos Aires, Argentina, from April 26 to October 31, 2020. Besides patients admitted for COVID-19, all cases which require hospitalization for other reasons were also tested. The diagnosis was made by identification of SARS-CoV-2 in nasopharyngeal secretions by RT-PCR.

In all cases, sex, age, place of residence (including whether they lived in a poor neighborhood [7]), time of symptoms onset on admission, close contact with a confirmed COVID-19 case, presence of comorbidity and length of hospitalization was registered.

Severity was assessed as described by Dong [8]; patients presenting with SARS-CoV-2-related multisystemic inflammatory syndrome (MIS-C) were considered severe/critical.

Lab tests were also recorded (hemoglobin, differential WBC count, platelets, C-reactive

protein, and erythrocyte sedimentation rate).

Statistical analysis: Categorical variables are described by proportions with 95% confidence

intervals (95%CI), and continuous variables by mean and standard deviation or median and

interquartile range (IQR), according to distribution (Kolmogorov-Smirnov test). IBM SSPS

Statistics 20.0 was used.

Ethics: The study was approved by the Institution Ethics Committee.

RESULTS

In the studied period, 578 children and adolescents were hospitalized for COVID-19. Some

characteristics of 191 of these patients were mentioned in a preliminary report in the

beginning of the pandemic [9]. Here we describe all patients hospitalized for COVID during

the whole cold season (May-October), including laboratory data.

The number of hospitalizations per week ranged between 2 and 42 (Median= 30.5; IQR=

21.7-35.7) (Fig. 1).

The median age was 4.2 (IQR: 0.7-11.2) years and 54.5% were male. Sixty-seven percent

(67.3%) had their residence within the jurisdiction of the hospital (City of Buenos Aires) and,

of them, 23.1% lived in a poor neighborhood.

Eighty-three percent (83%) had a history of close contact with a confirmed COVID-19 case.

The time of symptoms onset before admission was 1 day (IQR: 1-3). Thirty-five percent

(35.3%) had a previous or concomitant diagnosis of other disease, asthma being the most

frequent (n = 49) (Table 1).

Disease severity was assessed and 30.8% were considered asymptomatic, 60.4% mild, 7.4%

moderate, and 1.4% severe. From the six severe cases, only one required assisted ventilation,

and two presented with SARS-CoV-2-related multisystemic inflammatory syndrome (MIS-

C). Other six MIS-C cases were admitted to the hospital but SARS-CoV-2 testing was negative at that moment.

The most frequent initial symptom was fever, followed by sore throat and cough (Table 2). Regarding the lab tests, we found that 9.4% showed lymphopenia (lymphocyte differential count <20%) and 23.8% elevated C-reactive protein values (C-reactive protein > 10 mg/dl) (being 100% among severe cases and 10% among asymptomatics)(Table 3).

The length of stay had a median of 6 days (IQR: 2.2-9).

At the time of this report, only one patient with COVID 19 died, due to causes other than the disease, since he was in end-of-life care. All patients were discharged without complications (with phone follow-up), except those whose comorbidity prevented it.

DISCUSSION

Our study strengthens the idea that COVID 19 in pediatrics is, in general, mild. It also supports some characteristics of the disease in Argentina that our early report has suggested [9].

Although it is possible that the age structure (Argentina has twice the number of children under 15 years of age than Italy) and the social behaviour of the different populations influence the differences observed [10] [11], the way in which local health authorities dealt with the pandemic have generated some particular features in our patients: Buenos Aires reported more pediatric cases than other countries, and we found a higher proportion of asymptomatic and mild among those hospitalized.

The City of Buenos Aires, adopted a "test and trace" policy. This program was carried out more strongly in poor neighborhoods, which have a younger population [12]. Mandatory hospitalization was also established for infants, still asymptomatic [6] [13]. Furthermore,

those asymptomatic children and adolescents who did not have home conditions to comply with out-of-hospital isolation, were hospitalized for the isolation period [14].

In the period covered by this report (until 10/31/2020) the City of Buenos Aires reported

proportion than that initially reported in China (2.1 %) [16] and Italy [17], but closer to that

147,363 cases, of which 12.1% were children and adolescents [15], a substantially higher

lately reported in the USA (9%) [18].

We found a high proportion of asymptomatic patients (30.8%), higher than that reported by Götzinger in Europe in 582 children with SARS-CoV-2 infection (16%) [19], probably related to the above mentioned test and trace and institutional isolation policies adopted by the local health authorities. Despite this high number of asymptomatic children, the proportion of those with co-morbidity (35,3%) was similar to other series [20][21]. We only found 5.6% moderate and 1.2% severe cases. Dong et al. in China reported 5.9% severe and critical cases [8] and Tagarro in Spain reports that 9.7% of the cases in his series were severe [22]. Although a report from the United States showed that 32% of hospitalized pediatric patients with COVID-19 were admitted to a PICU, the limited average length of stay (2 days) and the limited proportion of subjects who required assisted ventilation (5.8%)

Regarding the cases of MIS-C (COVID-19 associated Multisystem Inflammatory Syndrome in Children) that we report, they presented 4 to 6 weeks after reaching a significant number of cases in our city, a moment described as usual for the development of this complication [23]. Finally, we have found that 83% of our patients had close contact with infected people, supporting the idea that children are usually infected from adults [24].

suggests that the admission criteria in this series were broader [21].

This study has the limitation of presenting data from a single center, although it is probably the public institution that has hospitalized the most pediatric patients with COVID-19 in our country. Moreover, including data for a single center shows that, in a winter with no RSV

related hospitalizations, the number of patients hospitalized for COVID-19 is roughly the same number we admit for RSV disease each year [25], whether this is related to nonpharmaceutical interventions used to control the pandemia or not [26].

CONCLUSION

In this study we report 578 cases of children and adolescents hospitalized for COVID-19 in Argentina. Most presented their disease as mild or asymptomatic, supporting the idea that the management of pediatric COVID-19 patients represents more an organizational challenge rather than any one specific clinical task [27].

REFERENCES

- Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109(6):1088-1095.
 doi:10.1111/apa.15270
- Hoang A, Chorath K, Moreira A, et al. COVID-19 in 7780 pediatric patients: A systematic review. EClinicalMedicine. 2020;24:100433. Published 2020 Jun 26. doi:10.1016/j.eclinm.2020.100433
- 3. Smit AJ, Fitchett JM, Engelbrecht FA, Scholes RJ, Dzhivhuho G, Sweijd NA. Winter Is Coming: A Southern Hemisphere Perspective of the Environmental Drivers of SARS-CoV-2 and the Potential Seasonality of COVID-19. Int J Environ Res Public Health. 2020;17(16):5634. Published 2020 Aug 5. doi:10.3390/ijerph17165634
- Tanne JH, Hayasaki E, Zastrow M, Pulla P, Smith P, Rada AG. Covid-19: how doctors and healthcare systems are tackling coronavirus worldwide. BMJ.
 2020;368:m1090. Published 2020 Mar 18. doi:10.1136/bmj.m1090
- 5. Pieper O. Coronavirus: Argentina 's never-ending quarantine. Deutsche Welle. 2020 Aug 27. [cited 2020 Nov 01]. Available from: https://www.dw.com/en/coronavirus-argentinas-never-ending-quarantine/a-54721129.
- 6. Ministerio de Salud, Gobierno de la Ciudad Autónoma de Buenos Aires. Manejo frente a casos sospechosos y confirmados de coronavirus (COVID 19) en pediatría.
 V.3. 8 de Mayo de 2020. pp 6. [cited 2020 Nov 02]. Available from https://www.buenosaires.gob.ar/sites/gcaba/files/p.pediatria8.05.pdf.
- Ministerio de Desarrollo Territorial y Hábitat. Registro Nacional de Barrios Populares. [cited 2020 Jun 25]. Available from: https://www.argentina.gob.ar/habitat/renabap.

- 8. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020;145(6):e20200702. doi:10.1542/peds.2020-0702
- 9. Cairoli H, Raiden S, Chiolo MJ, Di Lalla S, Ferrero F. Patients assisted at the Department of Medicine of a pediatric hospital at the beginning of the COVID-19 pandemic in Buenos Aires, Argentina. Arch Argent Pediatr 2020;118(6):418-426. Available from:

https://www.sap.org.ar/uploads/archivos/general/files_cb_cairoli_eng_13-10pdf_1602265826.pdf

- 10. Natale F, Ghio D, Tarchi D, Goujon D, Conte A. COVID-19 Cases and Case Fatality Rate by age. [cited 2020 Nov 02] Available from: https://ec.europa.eu/knowledge4policy/sites/know4pol/files/jrc120420_covid_risk_an_dage.pdf.
- 11. Dowd JB, Andriano L, Brazel DM, et al. Demographic science aids in understanding the spread and fatality rates of COVID-19. Proc Natl Acad Sci U S A. 2020;117(18):9696-9698. doi:10.1073/pnas.2004911117
- 12. Figar S, Pagotto V, Luna L, Salto J, Wagner Manslau M, Mistchenko A, Gamarnik A, Gomez Saldano AM, Quiros F. Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research. medRxiv 2020.07.14.20153858; [cited 2020 Nov 01]. Available from: https://www.medrxiv.org/content/10.1101/2020.07.14.20153858v2.
- 13. Ministerio de Salud, Gobierno de la Ciudad Autónoma de Buenos Aires. Manejo frente a casos sospechosos y confirmados de coronavirus (COVID 19). V.30. 7 de Junio de 2020. pp 6.

- 14. Ministerio de Salud, Gobierno de la Ciudad Autónoma de Buenos Aires. Manejo frente a casos sospechosos y confirmados de coronavirus (COVID 19). V.32. 19 de Junio de 2020. pp 16.
- 15. Ministerio de Salud, Gobierno de la Ciudad Autónoma de Buenos Aires.
 Actualización de los casos de coronavirus en la Ciudad. [cited 2020 Nov 01].
 Available from: https://www.buenosaires.gob.ar/coronavirus/noticias/actualizacion-de-los-casos-de-coronavirus-en-la-ciudad-buenos-aires.
- 16. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) China, 2020[J]. China CDC Weekly, 2020; 2(8):113-122. [cited 2020 Nov 18]Available from: http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51.
- 17. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020;323(14):1335. doi:10.1001/jama.2020.4344
- 18. CDC. CDC COVID Data Tracker: Demographic Trends of COVID-19 cases and deaths in the US reported to CDC. Atlanta, GA: US Department of Health and Human Services, CDC; 2020. [cited 2020 Nov 02]. Available from: https://www.cdc.gov/covid-data-tracker/index.html#demographics.
- 19. Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653-661. doi:10.1016/S2352-4642(20)30177-2
- 20. Rao S, Gavali V, Prabhu SS, Mathur R, Dabre LR, Prabhu SB, Bodhanwala M.
 Outcome of Children Admitted With SARSs-CoV-2 Infection: Experiences From a
 Pediatric Public Hospital. Indian Pediatr 2021; epub ahead of print. [cited 2021 Jan

- 15] Available from: https://www.indianpediatrics.net/COVID29.03.2020/RP-00280.pdf.
- 21. Kim L, Whitaker M, O'Halloran A, et al. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 -COVID-NET, 14 States, March 1-July 25, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1081-1088. Published 2020 Aug 14. doi:10.15585/mmwr.mm6932e3
- 22. Tagarro A, Epalza C, Santos M, et al. Screening and Severity of Coronavirus Disease 2019 (COVID-19) in Children in Madrid, Spain [published online ahead of print, 2020 Apr 8]. JAMA Pediatr. 2020;e201346. doi:10.1001/jamapediatrics.2020.1346
- 23. Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276-e288. doi:10.1016/S1473-3099(20)30651-4
- 24. Munro APS, Faust SN. Children are not COVID-19 super spreaders: time to go back to school. Arch Dis Child. 2020;105(7):618-619. doi:10.1136/archdischild-2020-319474
- 25. Ferrero F, Torres F, Abrutzky R, et al. Seasonality of respiratory syncytial virus in Buenos Aires. Relationship with global climate change. Arch Argent Pediatr. 2016;114(1):52-55. doi:10.5546/aap.2016.eng.52
- 26. Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections [published online ahead of print, 2020 Nov 9]. Proc Natl Acad Sci U S A. 2020;202013182. doi:10.1073/pnas.2013182117

27. Parri N, Lenge M, Cantoni B, et al. COVID-19 in 17 Italian Pediatric Emergency

Departments [published online ahead of print, 2020 Sep 23]. Pediatrics.

2020;e20201235. doi:10.1542/peds.2020-1235

Table 1. Comorbidities in pediatric patients hospitalized for COVID-19 (n=204/578)

Disease	n
Asthma	49
Surgical conditions (appendicitis, testicular torsion, hernias)	12
Seizures	11
Non-progressive chronic encephalopathy	11
Genetic disorders	9
Tumors	8
Tuberculosis	8
Other infections (otitis, celulitis, hepatitis)	8
Urinary tract infection	7
Obesity	5
Diabetes mellitus	5
Thrombocytopenic purpura	5
Chronic kidney disease	5
Chronic lung disease/Bronchopulmonary dysplasia	4
Congenital heart disease	3
Hemolytic-uremic syndrome	2
Hematologic disease (spherocytosis, hemophilia)	2

HIV	2
Other	48

Table 2. Initial symptom of symptomatic patients hospitalized for COVID-19 (n=400)

Symptom	n	%
Fever	207	51.7
Sore throat	49	12.2
Cough	40	10
Rhinorrhea	39	9.7
Headache	37	9.2
Diarrhea/vomiting	35	8.7
Dyspnea	17	4.2
Abdominal pain	15	3.7
Loss of smell	13	3.2
Rash	6	1.5
Loss of taste	3	0.7

(patients could have more than one symptom)

Table 3. Laboratory characteristics of children hospitalized for COVID-19

	Mean	SD
Hemoglobin (mg/dL)	12.5	1.4
White blood cells count (/mL)	8,062	3,889
Lymphocyte differential count (%)	49	20
Neutrophil differential count (%)	39	20
Platelet count (/mL)	289,544	106,073
Erythrocyte sedimentation rate (mm/1 h)	13	12
C-reactive protein (mg/dL)	14	38

Figure 1. Pediatric hospitalizations for COVID-19, according to epidemiological week

